Bifunctional Alpha-Synuclein Binding Agents for Neurodegenerative Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Parkinson's Disease do not effectively prevent or reverse the progression of alpha-synuclein aggregation, which is a key toxic event in the disease, and there is a need for diagnostic agents that can provide early diagnosis of Parkinson's Disease.
Innovation Solution
Development of bifunctional molecules comprising linked combinations of alpha-synuclein binding agents that can bind to alpha-synuclein, potentially inhibiting its aggregation and serving as imaging agents for PET scanning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current therapies (levodopa, rasagiline) are used to increase dopamine levels, then typical symptoms (resting tremor, slow movement) are alleviated, but the disease progressively worsens over 5-10 years leading to further cell death
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism (alpha-synuclein aggregation) rather than treating general symptoms. By removing the toxic aggregated alpha-synuclein through selective binding agents, the therapy addresses the root cause of progression while maintaining symptom management
Solution Approach 2:
The bifunctional molecules serve multiple purposes: they bind to alpha-synuclein to prevent aggregation, act as imaging agents for PET scanning to detect disease presence and progression, and provide both therapeutic and diagnostic capabilities in a single agent
2Reliability
If aggregated alpha-synuclein is allowed to accumulate, then the natural disease process occurs, but early diagnosis and intervention opportunities are lost
Solution Approach 1:
The imaging agents are designed to bind to alpha-synuclein aggregates at early stages of aggregation, enabling detection before significant neuronal damage occurs. This preliminary detection allows intervention at the optimal therapeutic window
Solution Approach 2:
The PET imaging agents utilize radioactive tracers that emit detectable signals when bound to alpha-synuclein, providing visual contrast that enables early detection of aggregates through imaging technologies
3Productivity
If single-function binding agents are used, then either therapeutic or diagnostic function is achieved, but both therapeutic and diagnostic needs require separate interventions
Solution Approach 1:
The bifunctional molecules integrate both therapeutic alpha-synuclein binding capability and diagnostic imaging capability into a single agent, eliminating the need for separate therapeutic and diagnostic interventions while improving overall treatment efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional molecules demonstrate the ability to prevent or delay alpha-synuclein aggregation, improve motor function in rat models, and have potential as both therapeutic and diagnostic tools for Parkinson's Disease.
Implementation Method 1
compounds that bind to alpha-synuclein with increased affinity
Implementation Method 2
potential utility as therapeutic agents in PET scanning
Data Source
AI summary
Bifunctional molecules having first and second alpha-synuclein binding agents coupled by a linker are disclosed. The bifunctional molecules have potential utility in the diagnosis, treatment and/or prophylaxis of disorders in which alpha-synuclein is implicated, including Parkinson's disease. Methods of making and using the bifunctional molecules are disclosed.